Session » (1123–1146) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

10:30AM-12:30PM

Abstract Number: 1135

A Gain-of-Function 5’UTR Variant in ANKH Causes Familial CPPD with Elevated Extracellular PPi and Citrate

10:30AM-12:30PM

Abstract Number: 1133

A Proteomic Analysis Of Subclinical Synovial Inflammation Associated With Monosodium Urate Crystal Deposition

10:30AM-12:30PM

Abstract Number: 1144

A quantitative study of renal medulla echogenicity in 250 Vietnames gout patients shows correlation with poor renal function

10:30AM-12:30PM

Abstract Number: 1124

ABCG2 Variants as Genetic Risk Factors for Hyperuricemia and Gout: Focus on Pediatric and Familial Manifestations

10:30AM-12:30PM

Abstract Number: 1128

Association between leptin levels, body mass index and health-related quality of life in patients with gout

10:30AM-12:30PM

Abstract Number: 1146

Association of Walking Volume and Intensity With Incident Gout: A Population-based Cohort Study

10:30AM-12:30PM

Abstract Number: 1126

Clinical Impact of Signs of Calcium Pyrophosphate Deposition Disease (CPPD) on Radiographs of Hands and Wrists in a Real-World Cohort of Patients with Early Rheumatoid Arthritis

10:30AM-12:30PM

Abstract Number: 1132

DDX3X Regulates Gout Inflammation via NLRP3 Inflammasome Activation and Macrophage Pyroptosis Crosstalk

10:30AM-12:30PM

Abstract Number: 1129

Effectiveness of sodium-glucose cotransporter type 2 inhibitors and urate-lowering agents in patients with gout: data from a single-center specialised clinic

10:30AM-12:30PM

Abstract Number: 1134

Efficacy and Safety of Anakinra for Acute Calcium Pyrophosphate Deposition Disease Flare: A Systematic Review and Meta-Analysis

10:30AM-12:30PM

Abstract Number: 1138

Efficacy of Pozdeutinurad (AR882) in Treatment Naïve and Suboptimally Treated Gouty Arthritis with Tophi

10:30AM-12:30PM

Abstract Number: 1143

Gout and Renal Failure-Related Mortality Trends in USA from 1999-2020: Analysis of CDC Wonder Database

10:30AM-12:30PM

Abstract Number: 1137

Increased Risk of Cardiovascular Events and Mortality Related to Diffuse Idiopathic Skeletal Hyperostosis (DISH): A Systematic Review and Meta-Analysis

10:30AM-12:30PM

Abstract Number: 1141

Modulation of Inflammatory Responses by Dental Pulp Stem Cell Extracellular Vesicles in Monosodium Urate-Stimulated Macrophages

10:30AM-12:30PM

Abstract Number: 1123

Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates Long Term Efficacy and Safety in Patients with Uncontrolled Gout: Results from the 24-week Double-blind Extension of the Phase 3 DISSOLVE I Study

10:30AM-12:30PM

Abstract Number: 1130

Novel Anti-Obesity Medications and Serum Urate Change Among Patients with Gout and Baseline Hyperuricemia

10:30AM-12:30PM

Abstract Number: 1145

Numerically Reduced but MSU Crystal-Activated NK Cells Promote Osteoclastogenesis in Gout

10:30AM-12:30PM

Abstract Number: 1140

PGG Suppresses MSU Crystal–Triggered Inflammation and Arachidonic Acid Production in PBMCs

10:30AM-12:30PM

Abstract Number: 1139

Synovial Counts, Cultures, and Crystals: An Analysis of 9,000 Aspirations

10:30AM-12:30PM

Abstract Number: 1136

The Impact of Iron Overload and HFE Genetic Mutations on Joint Disease in Haemochromatosis: Data from the Haemochromatosis Arthropathy Inception Cohorts

10:30AM-12:30PM

Abstract Number: 1127

The Pathogenetic Role of Calcium Pyrophosphate and Basic Calcium Phosphate Crystals in Osteoarthritis: Associations with Synovial Fluid Cytokines and Clinical Indices

10:30AM-12:30PM

Abstract Number: 1142

Tibial Bone Microstructure and Histomorphometry in Individuals with CPPD

10:30AM-12:30PM

Abstract Number: 1125

Validation of an Allopurinol Dose Prediction Tool to Achieve Goal Serum Urate Among Patients with Gout

10:30AM-12:30PM

Abstract Number: 1131

Variant Drives Tophus Formation through Dual Mechanisms: Extracellular Aggregation andvImpaired Macrophage Phagocytic Clearance